Investor Presentaiton
Commercialisation: Johns Hopkins COPD trial result
•
Has the capability of assessing regional ventilation defects, which is critical to optimising therapies.
Is a repeatable lung assessment tool in a cohort of COPD patients.
•
Illustrates distribution of airflow within the lungs, corresponding with COPD severity.
Mean Specific Ventilation (a.u.)
Ventilation Heterogeneity/
Ventilation Heterogeneity By Disease Severity
200
400
600
800
1,000
1,200
Inspiration
Expiration
1
2
GOLD score
4DMedical Limited | Investor Presentation | November 2022
Patient 2
Patient 1
Visit 1
RIGHT
LEFT
UPPER
RIGHT
Normalized Specific Ventilation
0
RIGHT
3
4
Normalized Specific Ventilation
0
R
Upper
MIDDLE
Middle
4DMedical™
Visit 2
Upper
LEFT
Middle
Lower
Lower
LOWER
LEFT
UPPER
RIGHT
LEFT
UPPER
MIDDLE
LOWER
Normalized Specific Ventilation
1
2
R
R
L
MIDDLE
R
L
LOWER
22View entire presentation